Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 21
- Registration Number
- NCT04863014
- Locations
- 🇺🇸
Saint Louis University, Saint Louis, Missouri, United States
🇨🇦Clinique des maladies lipidiques de Quebec, Quebec, Canada
🇺🇸Excel Medical Clinical Trials, LLC, Boca Raton, Florida, United States
COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers
- Conditions
- Interventions
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 295
- Registration Number
- NCT04852978
- Locations
- 🇺🇸
Regeneron Research Site, Dayton, Ohio, United States
Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT04811716
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇲🇾Hospital Sibu, Sibu, Sarawak, Malaysia
🇰🇷Yonsei University College of Medicine, Severance Hospital, Seoul, Korea, Republic of
Compassionate Use of Dupilumab
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT04776694
Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
- Conditions
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 353
- Registration Number
- NCT04709575
- Locations
- 🇩🇪
Regeneron Study Site, Hamburg, Germany
Expanded Access to REGN4461 for Patients With Lipodystrophy or Monogenic Obesity With Complications of Leptin Deficiency or Deficient Leptin Signaling
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT04710056
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT04698187
- Locations
- 🇺🇸
City of Hope National Medical Center, Robert Kang, MD, Duarte, California, United States
🇺🇸University Cancer & Blood Center, Athens, Georgia, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT04695977
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
🇺🇸Hartford Healthcare, Hartford, Connecticut, United States
COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 1149
- Registration Number
- NCT04666441
- Locations
- 🇺🇸
Regeneron Study Site, Falls Church, Virginia, United States
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 113
- Registration Number
- NCT04646005
- Locations
- 🇺🇸
Arizona Oncology Associates, Tucson, Arizona, United States
🇧🇪Universitair Ziekenhuis Gent, Gent, East Flanders, Belgium
🇧🇪CHIREC Delta Hospital / Chirec Cancer Institute, Brussels, Belgium